Edition:
India

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

54.10USD
20 Nov 2017
Change (% chg)

$-1.10 (-1.99%)
Prev Close
$55.20
Open
$54.00
Day's High
$54.39
Day's Low
$53.63
Volume
3,990,209
Avg. Vol
2,974,011
52-wk High
$66.80
52-wk Low
$53.63

Select another date:

Thu, Nov 16 2017

BRIEF-Cue Biopharma announces collaboration with Merck

* ‍Cue Biopharma says a strategic research collaboration and license agreement with Merck

BRIEF-Merck reports 6.5 pct passive stake in Spero Therapeutics as of Nov 6

* Merck & Co reports 6.5 percent passive stake in Spero Therapeutics Inc as of Nov 6 - SEC Filing​ Source text: [http://bit.ly/2z57b4q] Further company coverage:

BRIEF-Merck reports final results of any and all tender offers

* Merck & Co Inc - ‍offers expired at 5:00 p.m., New York City time, on Nov. 13, 2017​

BRIEF-Merck announces pricing of any and all tender offers

* Says ‍as of date of offers, aggregate outstanding principal amount of notes was about $2.95 billion​

FDA OKs Merck drug that prevents infection post-stem cell transplant

Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday.

UPDATE 1-FDA OKs Merck drug that prevents infection post-stem cell transplant

Nov 9 Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday.

FDA OKs Merck drug to stop infection post-stem cell transplant

Nov 9 Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday.

BRIEF-Merck receives FDA approval of Prevymis for prevention of CMV infection in allogeneic stem cell transplant patients

* Merck receives FDA approval of Prevymis (letermovir) for prevention of cytomegalovirus (CMV) infection and disease in adult allogeneic stem cell transplant patients

BRIEF-Merck & Co updates on investigation of co's Italian unit

* Merck & Co Inc says in July 2017, co learned that the prosecution office of Milan, Italy is investigating certain interactions - SEC filing

BRIEF-Merck announces any and all tender offers

* Merck & Co Inc - ‍Offers are being made upon, and are subject to, terms and conditions set forth in offer to purchase, dated Nov. 6, 2017​

Select another date: